shares of gamida cell ltd fell sharply in premarket trading wednesday after the developer of cell therapies said it was raising about 20 million in a dilutive public stock offering and that it had inked a commitment letter for 25 million in financing the boston company said it is selling more than 129 million shares at 155 apiece 21 below tuesdays closing price of 196 gamida said it also signed a commitment letter with funds managed by highbridge capital management llc for a 25 million convertible term loan secured by substantially all of its assets gamida which had nearly 60 million shares outstanding before the offering said it plans to use proceeds from the offering for activities to support the potential launch of its omidubicel celltherapy candidate along with the continued clinical development of its other product candidates gamida shares were recently down 18 to 161 in premarket trading